Topical nalfurafine exhibits anti-inflammatory and anti-pruritic effects in a murine model of AD.
Derphartox BV, Rotterdam, The Netherlands. Electronic address: info@derphartox.com.
Graham
G
Elliott
Derphartox BV, Rotterdam, The Netherlands.
Raymond
R
Vanwersch
Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.
Michael
M
Soeberdt
Department of Dermatology, Center for Chronic Pruritus, University Hospital Münster, Germany.
Dieter
D
Metze
Department of Dermatology, Center for Chronic Pruritus, University Hospital Münster, Germany.
Tobias
T
Lotts
Department of Dermatology, Center for Chronic Pruritus, University Hospital Münster, Germany.
Sonja
S
Ständer
Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.
Christoph
C
Abels
D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000982:Antipruritics / Q000494:pharmacology*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D007249:Inflammation; D008024:Ligands; D051379:Mice; D008807:Mice, Inbred BALB C; D017473:Receptors, Opioid, kappa / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D000982:Antipruritics; D008024:Ligands; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu